Translate Bio Announces Collaboration With Sanofi Pasteur to Develop Infectious Disease Vaccines

Translate Bio Announces Collaboration With Sanofi Pasteur to Develop Infectious Disease Vaccines

Firm News

Translate Bio, Inc., a clinical-stage mRNA therapeutics company developing a new class of medicines to treat diseases caused by protein or gene dysfunction, has entered into a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to five undisclosed infectious disease pathogens. Sanofi Pasteur, the vaccines global business unit of Sanofi (NYSE:SNY), will make an upfront payment of $45 million to Translate Bio, and the companies will conduct joint research and development activities to advance mRNA vaccines during an initial three-year research term.

The WilmerHale team representing Translate Bio in the collaboration agreement is led by Belinda Juran and Cynthia Mazareas, and includes Ariel Soiffer and Ryan Crane.

Read Translate Bio’s press release about the collaboration.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.